NeuroDerm Announces Streamlined U.S. Development Plan on ND0612H and ND0612L for the Treatment of PD


(November 11, 2015) - NeuroDerm announced that it has modified its U.S. development plan for ND0612H and ND0612L, the company's continuous, subcutaneously delivered levodopa/carbidopa product candidates for the treatment of Parkinson's disease. Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients. Read more…

Click for a printer friendly version

Back to top